Navigation Links
National Stem Cell Holding, Inc. Announces the Change of Its Name to Proteonomix, Inc.
Date:5/28/2008

MOUNTAINSIDE, N.J., May 28 /PRNewswire-FirstCall/ -- National Stem Cell Holding, Inc. (OTC: NHGI - News) today announced that it is taking steps to change its name to Proteonomix, Inc. The change will also entail a change in its trading symbol.

Michael Cohen, President/CEO, stated: "Our new name reflects the fact that we are emerging out of our research and development stage and commencing the commercialization of our technologies. These technologies relate in great part to the identification of proteins, and their structure and functions within the emerging biotherapeutics field."

Further, the Company intends to begin marketing its current portfolio biomarkers to research laboratories globally.

National Stem Cell Holding, Inc. is focused on developing therapeutics based upon the use of human cells and their derivatives by developing proprietary stem cell therapeutics with particular focus on diabetes and cardiac diseases. Stem Cell Therapy involves the introduction of healthy new stem cells to repair and replace damaged or lost cells and promises treatment of diseases previously regarded as incurable.

In addition to its work with stem cell therapeutics, it is also developing the capabilities of its wholly-owned subsidiaries: the Sperm Bank of NY (tissue bank) and in vitro fertilization (IVF) laboratory and National Stem Cell Blood Laboratories Inc. (cord blood bank) and its affiliate, ProteoDerm (anti-aging cosmetics derived from stem cells).

The Company is headquartered in Mountainside, NJ. For more information, please contact us at the company website: http://www.nationalstemcell.com or http://www.pinksheets.com .

About National Stem Cell Holding, Inc.

National Stem Cell Holding, Inc. is a hybrid biotechnology company focused on developing therapeutics based upon the use of human stem cells and their derivatives. The term 'hybrid' refers to both the business model as well its product line. The Company is developing a pipeline of proprietary stem cell therapeutics with particular focus on diabetes. Many of the currently incurable diseases associated with aging are caused by the degeneration of specific cell types in the body. These include but are not limited to: cancer, heart disease, diabetes, neurodegenerative diseases and auto immune conditions. In addition to its work with stem cell therapeutics, the Company is leveraging its commercial infrastructure and product development capabilities of its wholly-owned subsidiaries The Sperm Bank of NY (tissue Bank and IVF laboratory) and National Stem Cell Blood Laboratories Inc. (cord blood banking program), and its affiliate, Decouverte Cosmetique, Inc.(cosmetics). The Company's investigational products are focused on the improvement of the quality of life for patients and their families. The Company's multi-facetted R&D program has demonstrated results with over 10 patent applications and multiple products ready to enter the market. The Company is headquartered in Mountainside, NJ and has facilities at multiple academic institutions.

"Safe Harbor Statement"

Under The Private Securities Litigation Reform Act of 1995: The statements in the press release that relate to the company's expectations with regard to the future impact on the company's results from new products in development are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The results anticipated by any or all of these forward-looking statements may not occur. The Company undertakes no obligation to publicly release the result of any revisions to these forward-looking statements that may be made to reflect events or circumstances after the date hereof, or to reflect the occurrence of unanticipated events or changes in the Company's plans or expectations.

Contact:

Michael Cohen

187 Mill Lane

Mountainside, NJ 07052

Phone: (212)792-6188

ir@nationalstemcell.com


'/>"/>
SOURCE National Stem Cell Holding, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Israeli Scientists Recipients of 2008 International Adult Stem Cell Award
2. BioElectronics Corporation - Substantial International Expansion Producing Sustained Revenue Growth-Company Reaches Monthly Break Even
3. Elekta Sees Record Attendance and Record Number of Submitted Abstracts at International Leksell Gamma Knife(R) Society Meeting in Quebec, Canada
4. MagSense to Exhibit Its Scientific and Clinical Applications at International Magnetic Carriers Conference
5. Sangamo BioSciences Announces Presentation of Phase 1 Data of ZFP Therapeutic at International Society for Cellular Therapy (ISCT) Meeting
6. Intellect Neurosciences, Inc. Grants License for Certain Patents and Patent Applications to Wyeth and Elan Pharma International Ltd.
7. International Wound Care Experts, Medline Announce Pressure Ulcer Prevention Consensus Paper
8. Lentigen Corporation Receives Four Research Grants From the National Institutes of Health
9. LifeStem International, Inc. Announces Increased Revenues, Decreased Operating Expenses
10. Chindex International Announces Shelf Registration, Related Strategy and Guidance
11. Chindex International Announces Conference Call to Discuss Its Fiscal 2008 Fourth Quarter and Year End Results on Thursday, June 12, 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... 23, 2016  Blueprint Bio, a company dedicated to ... medical community, has closed its Series A funding round, ... "We have received a commitment from Forentis ... need to meet our current goals," stated Matthew ... runway to complete validation on the current projects in ...
(Date:6/23/2016)... ... June 23, 2016 , ... ... at the Pennsylvania Convention Center and will showcase its product’s latest features from ... also be presenting a scientific poster on Disrupting Clinical Trials in The Cloud ...
(Date:6/23/2016)... -- Amgen (NASDAQ: AMGN ) today announced a ... sciences incubator to accelerate the development of new therapies ... QB3@953 was created to help high-potential life science and ... stage organizations - access to laboratory infrastructure. ... "Amgen Golden Ticket" awards, providing each winner with one ...
(Date:6/22/2016)... , June 22, 2016 Research and ... Global Markets" report to their offering. ... billion in 2014 from $29.3 billion in 2013. The market is ... of 13.8% from 2015 to 2020, increasing from $50.6 billion in ... projected product forecasts during the forecast period (2015 to 2020) are ...
Breaking Biology Technology:
(Date:4/28/2016)... 28, 2016 First quarter 2016:   ... compared with the first quarter of 2015 The gross ... M (loss: 18.8) and the operating margin was 40% (-13) ... Cash flow from operations was SEK 249.9 M (21.2) , ... is unchanged, SEK 7,000-8,500 M. The operating margin for ...
(Date:4/15/2016)... 15, 2016 Research and ... Biometrics Market 2016-2020,"  report to their offering.  , ... , ,The global gait biometrics market is expected ... the period 2016-2020. Gait analysis generates ... be used to compute factors that are not ...
(Date:3/29/2016)... LegacyXChange, Inc. (OTC: LEGX ... Protect are pleased to announce our successful effort to ... of writing instruments, ensuring athletes signatures against counterfeiting and ... athletes on LegacyXChange will be assured of ongoing proof ... Bill Bollander , CEO states, "By inserting ...
Breaking Biology News(10 mins):